Dublin, Sept. 04, 2023 (GLOBE NEWSWIRE) -- The "Global 3D Printed Drugs Market (2023-2028) by Technology, Application, End User, and Geography, Competitive Analysis, Impact of Covid-19 and Ansoff Analysis" report has been added to ResearchAndMarkets.com's offering.
The Global 3D Printed Drugs Market is estimated to be USD 74.04 Mn in 2023 and is expected to reach USD 157.46 Mn by 2028, growing at a CAGR of 16.29%.
3D printed drugs are pharmaceuticals created utilizing 3D printing technology. This new technique enables precise control of medication composition, allowing for customized dosages and complex pharmacological combinations. Layers of active pharmaceutical ingredients (APIs) and binders are printed to manufacture the required drug. The use of 3D-printed pharmaceuticals has the potential to transform pharmaceutical manufacturing and personalized medicine.
An increase in demand for immediate soluble drugs is driving the market for 3D-printed drugs. Drugs can be made into instant-dissolving structures using 3D printing, making them easier to deliver, especially for patients who have difficulties swallowing or who require immediate relief. This technology allows for the development of fast soluble drugs, which match the changing needs of patients and healthcare practitioners.
Another important driver of the 3D printed medicines market is the increasing usage of 3D printing technology in the medical and healthcare industries. 3D printing enables precise drug dosage form customization, enabling personalized treatment and improving patient care. The diversity of the technology and its ability to build complex drug structures make it a powerful tool for drug discovery and production.
The market for 3D-printed drugs is also being fueled by the increasing use of personalized drugs and the production of combination medicines. 3D printing allows for creation of medications with customized dosages and compositions adapted to the needs of specific patients. Furthermore, the technique enables the development of combination medicines, in which different drugs are combined into a single printed dosage form, simplifying administration and enhancing treatment outcomes. The push toward personalized and combination therapy is driving the need for 3D-printed medications.
Constant technological advances in 3D printing processes create considerable prospects in the market for 3D printed drugs. Material advancements, printing resolution, and process optimization enable the fabrication of more complex and accurate drug structures, hence improving treatment efficacy, safety, and patient adherence.
The increase in healthcare investment in emerging markets gives the potential for the 3D printed drugs market to flourish. These nations invest in cutting-edge healthcare infrastructure and technologies, such as 3D printing. The use of 3D-printed drugs might help increase accessibility, affordability, and personalized healthcare solutions in these regions, hence driving market growth.
However, the possibility for antagonistic pharmacological effects is one limitation in the 3D printed pharmaceuticals business. The interaction of multiple active pharmaceutical ingredients (APIs) in complex drug combinations generated by 3D printing can result in unexpected interactions or reduced effectiveness, providing issues for drug formulation and safety assurance.
The presence of severe government rules for 3D printed drugs is a major market challenge in the 3D printed pharmaceuticals business. Because of the manufacturing process's unique nature and personalized medicine components, regulatory organizations must create clear norms and criteria for quality control, safety, and efficacy of 3D-printed medications, which can be difficult. Compliance with these rules complicates and extends the time it takes to develop and commercialize 3D-printed pharmaceuticals.
Market Dynamics:
Drivers:
- Surge in Demand for Instantaneous Soluble Drugs
- Increasing Use of 3D Printing Techniques in the Medical & Healthcare Industries
- Growing Adoption of Personalized Drugs and Production of Combination Medicine
Restraints:
- Antagonistic Effects Related to Drugs
Opportunities:
- Constant Technological Developments in 3D Printing Techniques
- Rise in Health Care Investment in Emerging Countries
Challenges:
- Stringent Government Regulations for 3D Printed Products
Companies Mentioned:
- 3D Systems, Corp.
- Abbott Laboratories
- Anatomics, Pty. Ltd.
- Aprecia Pharmaceuticals, LLC
- AstraZeneca
- Bioduro-Sundia
- Biomedical Modeling, Inc.
- Esko
- FabRx Ltd.
- GE Healthcare
- GlaxoSmithKline
- Materialise NV
- Merck Group
- Novartis
- Renishaw PLC
- Siemens Ag
- Stratasys, Ltd.
- Teva Pharmaceuticals Ltd.
- Triastek, Inc.
- Zortrax
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 189 |
| Forecast Period | 2023 - 2028 |
| Estimated Market Value (USD) in 2023 | $74.04 Million |
| Forecasted Market Value (USD) by 2028 | $157.46 Million |
| Compound Annual Growth Rate | 16.2% |
| Regions Covered | Global |
For more information about this report visit https://www.researchandmarkets.com/r/fmvuk9
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
